|
|
Article: Data: Indiplon modified release demonstrates lack of respiratory side effects.
- Article from:
- Health & Medicine Week
- Article date:
- May 31, 2004
CopyrightCOPYRIGHT 2004 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2004 MAY 31 - (NewsRx.com & NewsRx.net) -- Neurocrine Biosciences, Inc., (NBIX) announced results from two phase I studies demonstrating that indiplon modified release does not affect respiratory functioning in healthy subjects or those with mild-to-moderate chronic obstructive pulmonary disease (COPD).
These results were presented at the annual meeting of the American Psychiatric Association (APA) in New York City, New York.
The first study presented was conducted in 12 healthy male volunteers in a double-blind crossover design with indiplon modified release 30 mg, codeine sulfate 60 mg (as a positive control), or placebo. Indiplon modified release ...